Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 210
Gene Symbol: ALAD
ALAD
0.500 Biomarker disease CTD_human Characterization of chemically induced liver injuries using gene co-expression modules. 25226513 2014
Entrez Id: 2200
Gene Symbol: FBN1
FBN1
0.500 Biomarker disease CTD_human Gene Expression Patterns Associated With Histopathology in Toxic Liver Fibrosis. 26396155 2016
Entrez Id: 2200
Gene Symbol: FBN1
FBN1
0.500 Biomarker disease RGD Fibrillin-1 expression in normal and fibrotic rat liver and in cultured hepatic fibroblastic cells: modulation by mechanical stress and role in cell adhesion. 14661032 2004
Entrez Id: 210
Gene Symbol: ALAD
ALAD
0.500 Biomarker disease RGD Delta-Aminolevulinate synthase and delta-aminolevulinate dehydratase activities were determined in liver biopsy specimens obtained from 12 patients with hepatic cirrhosis. 6848403 1983
Entrez Id: 540
Gene Symbol: ATP7B
ATP7B
0.410 CausalMutation disease CLINVAR
Entrez Id: 540
Gene Symbol: ATP7B
ATP7B
0.410 Biomarker disease CTD_human Wilson disease (WD) is caused by accumulation of excess copper (Cu) due to a mutation in the gene encoding the liver Cu transporter ATP7B, and is characterized by acute liver failure or cirrhosis and neuronal cell death. 25134866 2014
Entrez Id: 540
Gene Symbol: ATP7B
ATP7B
0.410 Biomarker disease BEFREE Experimental studies in mutant mice in which the copper-transporting ATPase gene (Atp7b) is disrupted revealed a drastic, time-dependent accumulation of hepatic copper that is accompanied by formation of regenerative nodes resembling cirrhosis. 25704483 2015
Entrez Id: 213
Gene Symbol: ALB
ALB
0.400 AlteredExpression disease BEFREE Albumin mRNA was not found in peripheral blood from normal humans (0 of 6), from patients with liver cirrhosis (0 of 10), from other tumors metastatic to liver (0 of 10), or during liver transplant surgery for cirrhosis (0 of 10). 7843713 1995
Entrez Id: 3569
Gene Symbol: IL6
IL6
0.400 Biomarker disease BEFREE We prospectively assessed the influence of 6 single nucleotide polymorphisms (SNPs) in TNFα, IL6, and IL1β genes on the risk of hepatocellular carcinoma (HCC) in patients with cirrhosis. 24751829 2014
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
0.400 GeneticVariation disease BEFREE During follow-up, two patients of the control group and three patients of the IFN group developed cirrhosis, and one of the IFN- treated patients progressed to hepatocellular carcinoma. 16012762 2005
Entrez Id: 3569
Gene Symbol: IL6
IL6
0.400 Biomarker disease CTD_human Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. 12830005 2003
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease LHGDN Vascular endothelial growth factor (VEGF) and its soluble receptors: sVEGF-R1, sVEGF-R2 were measured in plasma of 78 patients with liver cirrhosis by ELISA.Results. 18656381 2008
Entrez Id: 5265
Gene Symbol: SERPINA1
SERPINA1
0.400 Biomarker disease BEFREE We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change. 29427759 2018
Entrez Id: 3569
Gene Symbol: IL6
IL6
0.400 AlteredExpression disease BEFREE We also sought to determine whether levels of serum interleukin-6 (IL-6), lipopolysaccharide-binding protein, and soluble TNF-α receptor, along with the presence of bacterial DNA (bactDNA) in ascitic fluid, are appropriate markers for BT in patients with liver cirrhosis and SBP. 26725065 2016
Entrez Id: 3569
Gene Symbol: IL6
IL6
0.400 AlteredExpression disease BEFREE The current work was engrossed to weigh the potential role of Cichorium intybus linn against thioacetamide (TAA)-induced liver cirrhosis and their probable underlying biochemical and molecular mechanisms. farnesoid-X-receptor (FXR) expression, proliferating cell nuclear antigen (PCNA) immunoreactivity, and activated AMP protein kinase (pAMPK), sirtuin-1 (SIRT1), and interleukin-6 (IL6) levels were estimated in hepatic tissue by real-time PCR, immunohistochemistry, and immunoassay, respectively. 31368578 2019
Entrez Id: 213
Gene Symbol: ALB
ALB
0.400 Biomarker disease BEFREE To assess the benefits and harms of any plasma volume expanders such as albumin, other colloids (polygeline, dextrans, hydroxyethyl starch solutions, fresh frozen plasma), intravenous infusion of ascitic fluid, crystalloids, or mannitol versus no plasma volume expander or versus another plasma volume expander for paracentesis in people with cirrhosis and large ascites. 31251387 2019
Entrez Id: 3082
Gene Symbol: HGF
HGF
0.400 AlteredExpression disease BEFREE They also exhibited a significantly greater repair potential in relation to cirrhosis pathology and impaired liver function than did DPSCs expressing HGF at physiological levels. 29150644 2017
Entrez Id: 3569
Gene Symbol: IL6
IL6
0.400 Biomarker disease BEFREE It is indicated that targeting Gpr110 and activating the IL-6/STAT3 pathway may be considered to be preventive methods for some cirrhosis transition. 28401002 2017
Entrez Id: 213
Gene Symbol: ALB
ALB
0.400 Biomarker disease BEFREE Immunopositive staining for albumin (Alb) and cytokeratin 18 (CK18), and reverse transcription-polymerase chain reaction (RT-PCR) for Alb, alpha fetoprotein (AFP), CK18, cytokeratin 19 (CK19) ascertained that MSC-HGF-CNP treatment could be an effective combination to repopulate liver parenchymal cells in the liver cirrhosis. 21526984 2011
Entrez Id: 213
Gene Symbol: ALB
ALB
0.400 AlteredExpression disease BEFREE Branched-chain amino acids (BCAA) are valuable in the treatment of liver cirrhosis because they increase serum albumin levels. 27189838 2017
Entrez Id: 2147
Gene Symbol: F2
F2
0.400 GeneticVariation disease BEFREE The following thrombotic factors were evaluated in 68 hepatitis C patients with prothrombin activity >/= 80% (34 consecutive patients with extensive fibrosis and/or cirrhosis compared with 34 consecutive patients without extensive fibrosis and/or cirrhosis): factor V Leiden, G20210A prothrombin mutation, antithrombin, protein C and S deficiencies, hyperhomocysteinemia, elevated factor VIII level, and lupus anticoagulant. 15056097 2004
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
0.400 Biomarker disease BEFREE As a result of the exceedingly high cost of DAAs in many countries, IFN-free DAA regimens are mostly reserved to patients with advanced fibrosis or cirrhosis. 26725891 2016
Entrez Id: 2147
Gene Symbol: F2
F2
0.400 GeneticVariation disease BEFREE Plasma concentrations of factor II, VII, X, V, protein C (PC) total protein S (tPS) antithrombin (AT) and D-dimers (DD) were measured in 13 LC patients with PVT heterozygous for PT G20210A, in 13 LC patients with PVT without PT G20210A and in 13 LC controls matched by age, sex and Child-Pugh score. 16493481 2006
Entrez Id: 5265
Gene Symbol: SERPINA1
SERPINA1
0.400 GeneticVariation disease LHGDN The presence of the relatively high frequency of A1AT S and HFE H63D allele carriers in Egyptian cases of HCV liver cirrhosis suggest the necessity to implement routine molecular analysis of these genes for detection of risk genotypes among affected families. 16802007 2006
Entrez Id: 213
Gene Symbol: ALB
ALB
0.400 Biomarker disease BEFREE A comparative pharmacokinetic study of recombinant human serum albumin with plasma-derived human serum albumin in patients with liver cirrhosis. 18199895 2008